Shingrix: a New Herpes Zoster Vaccine

Thursday, December 21, 2017 at 12:00 PM ET / 9:00 AM PT
Duration: 20 minutes

Patients will hear that Shingrix is about 97% effective in preventing shingles, compared to about 51% with Zostavax.  Be prepared to answer their questions.

This month's TRC Hot Topic webinar features an expert panel discussion about Shingrix, a new shingles vaccine. Listen as Kathleen Dooling, MD, MPH, Adam Welch, PharmD, MBA, BCACP, FAPhA and other panelists answer common clinical questions about the new vaccine, including:
  • How does the efficacy of Shingrix compare to Zostavax?
  • How do Shingrix and Zostavax vaccine formulations differ?
  • Should Shingrix be used instead of Zostavax?
  • Will insurance companies pay for Shingrix instead of Zostavax?
  • Do injection-site reactions differ between Shingrix and Zostavax?